NASDAQ:INOV - Inovalon Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $14.33 +0.12 (+0.84 %) (As of 05/21/2019 04:00 PM ET)Previous Close$14.21Today's Range$14.25 - $14.5452-Week Range$9.19 - $15.57Volume237,300 shsAverage Volume515,636 shsMarket Capitalization$2.20 billionP/E Ratio79.61Dividend YieldN/ABeta0.71 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Inovalon Holdings, Inc., a technology company, provides cloud-based platforms empowering data-driven healthcare. It operates the Inovalon ONE Platform, a cloud-based platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities. In addition, it offers advisory, implementation, and support services. The company serves health plans and provider organizations, as well as pharmaceutical, medical device, and diagnostics companies. Its platforms include information of data pertaining to approximately 964,000 physicians; 519,000 clinical facilities; and approximately 264 million individuals and 42 billion medical events. Inovalon Holdings, Inc. was founded in 1998 and is headquartered in Bowie, Maryland. Receive INOV News and Ratings via Email Sign-up to receive the latest news and ratings for INOV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Data processing & preparation Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:INOV Previous Symbol CUSIPN/A CIK1619954 Webhttp://www.inovalon.com/ Phone301-809-4000Debt Debt-to-Equity Ratio1.46 Current Ratio1.89 Quick Ratio1.89Price-To-Earnings Trailing P/E Ratio79.61 Forward P/E Ratio38.73 P/E Growth2.75 Sales & Book Value Annual Sales$527.68 million Price / Sales4.16 Cash Flow$0.8415 per share Price / Cash Flow17.03 Book Value$4.37 per share Price / Book3.28Profitability EPS (Most Recent Fiscal Year)$0.18 Net Income$-39,160,000.00 Net Margins-5.28% Return on Equity6.43% Return on Assets2.30%Miscellaneous Employees2,499 Outstanding Shares153,250,000Market Cap$2.20 billion Next Earnings Date8/7/2019 (Estimated) OptionableOptionable Inovalon (NASDAQ:INOV) Frequently Asked Questions What is Inovalon's stock symbol? Inovalon trades on the NASDAQ under the ticker symbol "INOV." How were Inovalon's earnings last quarter? Inovalon Holdings Inc (NASDAQ:INOV) announced its quarterly earnings data on Wednesday, May, 1st. The technology company reported $0.10 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.07 by $0.03. The technology company had revenue of $145.50 million for the quarter, compared to analysts' expectations of $143.75 million. Inovalon had a positive return on equity of 6.43% and a negative net margin of 5.28%. The firm's quarterly revenue was up 56.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.04) EPS. View Inovalon's Earnings History. When is Inovalon's next earnings date? Inovalon is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for Inovalon. What guidance has Inovalon issued on next quarter's earnings? Inovalon updated its FY19 earnings guidance on Wednesday, May, 1st. The company provided earnings per share (EPS) guidance of $0.42-0.48 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.42. The company issued revenue guidance of $637-657 million, compared to the consensus revenue estimate of $632.95 million.Inovalon also updated its Q2 guidance to $0.09-0.11 EPS. What price target have analysts set for INOV? 3 brokers have issued 12-month price objectives for Inovalon's stock. Their forecasts range from $11.00 to $22.00. On average, they expect Inovalon's share price to reach $15.3333 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price. View Analyst Price Targets for Inovalon. What is the consensus analysts' recommendation for Inovalon? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovalon in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inovalon. Has Inovalon been receiving favorable news coverage? News coverage about INOV stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Inovalon earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave media headlines about the technology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. Who are some of Inovalon's key competitors? Some companies that are related to Inovalon include StoneCo (STNE), Proofpoint (PFPT), Zynga (ZNGA), Pegasystems (PEGA), YY (YY), Bilibili (BILI), CarGurus (CARG), Corelogic (CLGX), Globant (GLOB), Five9 (FIVN), Yext (YEXT), Evertec (EVTC), MINDBODY (MB), Upwork (UPWK) and Cars.com (CARS). What other stocks do shareholders of Inovalon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inovalon investors own include ConforMIS (CFMS), OncoSec Medical (ONCS), Genworth Financial (GNW), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Opko Health (OPK), Alibaba Group (BABA), General Electric (GE), Agenus (AGEN) and Coeur Mining (CDE). Who are Inovalon's key executives? Inovalon's management team includes the folowing people: Keith R. Dunleavy, CEO & Chairman (Age 50)Mr. Robert A. Wychulis, Pres (Age 64)Mr. John Michael Burgin, Chief Product Officer (Age 45)Mr. Jonathan R. Boldt, Chief Financial Officer (Age 34)Mr. Jason B. Capitel, Chief Operating Officer (Age 47) When did Inovalon IPO? (INOV) raised $500 million in an IPO on Thursday, February 12th 2015. The company issued 22,200,000 shares at $21.00-$24.00 per share. Goldman Sachs, Morgan Stanley, Citigroup, BofA Merrill Lynch and UBS Investment Bank acted as the underwriters for the IPO and Baird, Piper Jaffray, Wells Fargo Securities and William Blair were co-managers. Who are Inovalon's major shareholders? Inovalon's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (4.00%), BlackRock Inc. (3.30%), Neuberger Berman Group LLC (2.22%), Parametric Portfolio Associates LLC (0.67%), Northern Trust Corp (0.64%) and Geode Capital Management LLC (0.59%). Company insiders that own Inovalon stock include Jason Capitel, Keith R Dunleavy, Lee D Roberts, Robert A Wychulis and Shauna L Vernal. View Institutional Ownership Trends for Inovalon. Which institutional investors are selling Inovalon stock? INOV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Neuberger Berman Group LLC, Cowen Prime Services LLC, BlackRock Inc., Parametric Portfolio Associates LLC, Riverbridge Partners LLC, Morgan Stanley and Isthmus Partners LLC. View Insider Buying and Selling for Inovalon. Which institutional investors are buying Inovalon stock? INOV stock was purchased by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC, Sawgrass Asset Management LLC, Geode Capital Management LLC, Wade G W & Inc., Penn Davis Mcfarland Inc., Tibra Equities Europe Ltd, JPMorgan Chase & Co. and California Public Employees Retirement System. Company insiders that have bought Inovalon stock in the last two years include Jason Capitel, Keith R Dunleavy and Lee D Roberts. View Insider Buying and Selling for Inovalon. How do I buy shares of Inovalon? Shares of INOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Inovalon's stock price today? One share of INOV stock can currently be purchased for approximately $14.33. How big of a company is Inovalon? Inovalon has a market capitalization of $2.20 billion and generates $527.68 million in revenue each year. The technology company earns $-39,160,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Inovalon employs 2,499 workers across the globe. What is Inovalon's official website? The official website for Inovalon is http://www.inovalon.com/. How can I contact Inovalon? Inovalon's mailing address is 4321 COLLINGTON ROAD, BOWIE MD, 20716. The technology company can be reached via phone at 301-809-4000 or via email at [email protected] MarketBeat Community Rating for Inovalon (NASDAQ INOV)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 247 (Vote Outperform)Underperform Votes: 304 (Vote Underperform)Total Votes: 551MarketBeat's community ratings are surveys of what our community members think about Inovalon and other stocks. Vote "Outperform" if you believe INOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INOV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: What is the price-sales ratio? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.